Cargando…
The transfer of genetically engineered lymphocytes in melanoma patients: a Phase I dose escalation study
Autores principales: | Regan, Courtney, Nishimura, Michael, Le Poole, I Caroline, Godellas, Constantine, Stiff, Patrick, Garrett-Mayer, Elizabeth, Li, Mingli, Shirai, Keisuke, Eby, Jonathan, Embree, Heather, Dropulic, Boro, Clark, Ann Lau, Hutchens, Kelli, Clark, Joseph I |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645562/ http://dx.doi.org/10.1186/2051-1426-3-S2-P168 |
Ejemplares similares
-
Genetically engineered lymphocytes in metastatic melanoma: TIL 1383I TCR transduced T-cells are detectable after infusion
por: Regan, Courtney, et al.
Publicado: (2013) -
Complications of sequential immunotherapy in metastatic melanoma
por: Bufalino, Shams, et al.
Publicado: (2015) -
HDAC inhibition prevents transgene expression downregulation and loss-of-function in T-cell-receptor-transduced T cells
por: Moore, Tamson V., et al.
Publicado: (2021) -
Stable Transcriptional Repression and Parasitism of HIV-1
por: Shrivastava, Surya, et al.
Publicado: (2018) -
Advances in Lentiviral Vector-based Cell Therapy with Mesenchymal Stem Cells
por: Baranyi, Lajos, et al.
Publicado: (2012)